Bevacizumab in colorectal cancer [2] (multiple letters)

New England Journal of Medicine

Volumn 351, Issue 16, 2004, Pages 1690-1691

  Sonpavde, Guru ^a   Sharieff, Waseem ^b   Hurwitz, Herbert I ^c   Novotny, William ^d   Kabbinavar, Fairooz ^e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d GENENTECH INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; CAMPTOTHECIN; DRUG DERIVATIVE;

COLORECTAL CANCER; DISEASE COURSE; HUMAN; LETTER; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESEARCH ETHICS; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; ETHICS; METASTASIS; METHODOLOGY; NOTE; RANDOMIZED CONTROLLED TRIAL; DISEASE FREE SURVIVAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; CROSS-OVER STUDIES; DISEASE PROGRESSION; HUMANS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; CAMPTOTHECIN; DISEASE-FREE SURVIVAL; FLUOROURACIL; LEUCOVORIN; QUALITY-ADJUSTED LIFE YEARS;

EID: 19544391606     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200410143511622     Document Type: Letter

References (0)